OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
OPKO Health, Inc. (NASDAQ: OPK) will announce its financial results for the first quarter of 2023 on May 3, 2023, after market close. The company plans to host a conference call and webcast to discuss the results and provide financial guidance at 4:30 p.m. Eastern time on the same day. Interested participants are encouraged to pre-register for the call to receive a unique PIN for immediate access. A replay of the call will be available until May 10, 2023. OPKO is focused on establishing leading positions in biopharmaceuticals and diagnostics through its proprietary technologies and expertise.